lung injury Upgrades to CareDx's AlloSure Test Enable Earlier Detection of Transplant Rejection Premium AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment. CareDx Expands AlloSure Transplant Test to Lung, Starting With Compassionate Use Premium The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients. Liquid Biopsy Dx Looks for Donor-Derived DNA as Measure of Chronic Lung Transplant Rejection Premium A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants. Silence Puts Sepsis Program on Backburner as it Advances Cancer Drug Premium NEW YORK (GenomeWeb) – Silence Therapeutics this month disclosed that it was ending its work with investigational sepsis drug Atu112 amid disappointing results in preclinical testing. Silence Plans $28.6M Stock Sale to Fund Expansion of Staff, Pipeline Premium Silence Therapeutics this week announced that it is closing in on a much-needed financial shot in the arm, inking deals to raise £18.7 million ($28.6 million) through the private placement of 9.5 million shares to certain investors. Sep 13, 2012 Silence Says Lung Injury Drug Shows Promise in Animal Study Premium Mar 22, 2012 Silence Says Cash Runway Ends in Q3, Directors Have 'Uncertainty' About Additional Fundraising Premium Feb 16, 2012 With New CEO, Silence Looks to Find Partners and Advance a New Drug into the Clinic Premium Jun 2, 2011 Silence Raises Nearly $10M, Provides Timeline for Pipeline Programs Premium Feb 4, 2009 23andMe, MondoBiotech Collaborate to Study Genetic Risk for Rare Diseases Premium Breaking News Bio-Rad Laboratories Q2 Revenues Climb 33 Percent, Beat Estimates Veracyte Q2 Revenues More Than Double on Test Volume Spike Increased Testing Revenues Boost Opko Health Q2 Revenues 47 Percent Qiagen Q2 Revenues Grow 28 Percent CareDx Q2 Revenues Up 77 Percent Secondary Genetic Findings Often Requested if Given Second Chance, Study Finds The Scan Booster Push New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high. With Help from Mr. Fluffington, PurrhD Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic. Man Charged With Threatening to Harm Fauci, Collins The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials. Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.